Title: Lipid Profile in Type 2 Diabetes Mellitus with and Without Subclinical Hypothyroidism
Authors: S. P. Jadkar, J. V. Ganu, K. N. Pujari, Milind Patwardhan, Varsha Patwardhan
DOI: http://dx.doi.org/10.18535/jmscr/v4i6.21
In clinical practice, Diabetes Mellitus is the most common endocrine disorder. The prevalence of thyroid disorders is higher in diabetic patients as compared to general population and the most common disorder being subclinical hypothyroidism. Subclinical hypothyroidism has been claimed to be a risk factor for coronary artery disease, peripheral vascular disease and various biochemical abnormalities including dyslipidemia. The present study was planned to measure serum lipids such as total cholesterol, triglycerides, low density lipoprotein- cholesterol and high density lipoprotein- cholesterol in type 2 diabetics with and without subclinical hypothyroidism. Study includes 200 patients of type 2 diabetics with subclinical hypothyroidism and 200 type 2 diabetics without subclinical hypothyroidism. The data were evaluated statistically. We found significantly increase in total cholesterol, triglycerides and low density lipoprotein- cholesterol (p<0.001) and significantly decreased high density lipoprotein- cholesterol (p<0.001) in type 2 diabetes mellitus with subclinical hypothyroidism before therapy as compared to type 2 diabetes mellitus without subclinical hypothyroidism. After L-thyroxine therapy we observed highly significant reduction in total cholesterol, triglycerides and low density lipoprotein- cholesterol (p<0.001) and significantly increase in high density lipoprotein- cholesterol (p<0.001) in type 2 diabetes mellitus with subclinical hypothyroidism as compared to before therapy. Subclinical hypothyroidism is associated with atherogenic serum lipid profile pattern. Such pattern may increase the risk of atherosclerosis and CVD. L-thyroxine is of utmost importance to reduce or prevent the risk of development of atherosclerosis and CVD in type 2 DM with SCH patients. Key Words: Diabetes Mellitus, Subclinical hypothyroidism, Cardiovascular disease, Lipid profile. 1. Vinu Vij, Pallavi Chitnis, Vijay Kumar Gupta. Evaluation of thyroid dysfunction among type II diabetic patients. International Journal of Pharmacy and Biological Sciences Oct- Dec 2012; 2(4): 150-155. 2. Satvic C. Manjunath, Vishwanath Krishnamurthy, Balaraj K. Puttaswamy, Srinivasa Prabhu, Poornachandra M. Vishwanathaiah. Prevalence of subclinical thyroid disorders in type 2 diabetes mellitus. International Journal of Medicine and Public Health Oct- Dec 2013: 3(4):330-334. 3. S. Senthikumaran, V. Sathyaprakash and A. Sundhararajan. A study on prevalence and distribution of subclinical hypothyroidism in rural women. Scholars journal of Applied Medical Sciences 2015; 3(1D):287-290. 4. DF 40. Shivaleela M. Biradar and Santosh R. Patil. Study of lipid profile in subclinical hypothyroidism. International Journal of Pharma and Bio Sciences july 2015; 6(3):B1-6. 5. Makandar Asmabi, Sonagra Amit D, Biradar Shivaleela M and Quadri Shireen Swaliha. Effect of thyroid dysfunction on metabolic response in type 2 diabetic patients. Unique Journal of Medical and Dental Sciences 2015; 3(1):65-69. 6. Karoon Shahebrahimi, Rozita Naseri, Tahereh Sadat Kalantarian, Mehrali Rahimi, Farid Najafi, Katayoun Derakhshandeh, Azam Sharifi. Effects of levothyroxine treatment on lipid profile in subclinical hypothyroidism: a randomized clinical trial. Galen Medical Journal 2015; 4(2):72-77. 7. Rifai N.,et al.,Lipids, Lipoproteins, and Apolipoproteins. Teitz Fundamentals of Clinical chemistry, 5th Ed, Burtis, C.A. & Ashwood, E.R. by W. B. Saunders Philadelphia USA), 2001,463. 8. Naito, H K, Coronary Artery Disease and Disorders of Lipid Metabolism. Clinical Chemistry: Theory, Analysis, Correlation, 4th Ed., Kaplan, L.A., Pesce, A J., Kazmierczak, S C by Mosby, Inc. eds. St Louis USA, 2003,603. 9. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with enzyme that produces hydrogen peroxide. Clin Chem, 1982, 28:2077. 10. Tietz NW. Clinical guide to laboratory tests, 3rd edition by Saunders Philadelphia USA), 1995,610. 11. Dominiczak M, McNamara J. The system of cardiovascular prevention: in 103-125; Nauk M, Wiebe D, Warnick G. Measurement of high density lipoprotein cholesterol. 221-244. In: handbook of lipoprotein testing (eds. Rifai, Warnick and Dominiczak), 2nd edition. 12. Hongbing Xiao. Method and composition for determining low density lipoprotein cholesterol. Chinese Patent CN 1379234A (2002). 13. D. F. 32. Sarika Singh and Purnima Dey Sarkar. Lipids, oxidative stress and new emerging cardiac risk markers in subclinical hypothyroidism: before and after treatment. Journal of Pharmaceutical and Biological Sciences 2013; 1(5):61-65. 14. D.F. 36. Sarika Singh and Purnima Dey Sarkar. Serum lipids, tHcy, hs-CRP, MDA and PON-1 levels in SCH and overt hypothyroidism: effect of treatment. Acta Biomed 2014; 85(2):127-134. 15. D.F. 35. Adriana Santi, Marta M.M.F. Duarte, Charlene C. de Menezes and Vania Lucia Loro. Association of lipids with oxidative stress biomarkers in subclinical hypothyroidism. International journal of Endocrinology 2012; Article ID 856357:1-7. 16. D. F. 37. Wei Zhang, Li-min Tian, Yong Han, Hong-yan Ma, Lai-cheng Wang, Jun Guo, Ling Gao and Jia-Jun Zhao. Presence of thyrotropin receptor in hepatocytes: not a case of illegitimate transcription. J Cell Mol Med 2009; 13(11-12):4636-4642. 17. D.F. 38. Furong Wang, Yinyin Tan, Chenggang Wang, Xu Zhang, Yuanfei Zhao, Xinhong Song, Bingchang Zhang, Qingbo Guan, Jin Xu, Ji Zhang, Dongzhi Zhang, Haiyan Lin, Chunxiao Yu and Jiajun Zhao. Thyroid stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormone. J Clin Endocrinol Metab 2012; 97:2724-2731. 18. D. F. 39. Amit Saxena, Pragati Kapoor, Shikha Saxena and A K Kapoor. Effect of levothyroxine therapy on dyslipidemia in hypothyroid patients. Internet Journal of medical update, July 2013; 8(2):39-49. Abstract
References